Eric Padron, MD, shares results from the phase I study of ruxolitinib in chronic myelomonocytic leukemia, a rare type of myelodysplastic, myeloproliferative neoplasm with few treatment options.
Ruxolitinib in CMML: Study Shows Promising Results
Recent Articles
FDA Announces New Plans to Regulate Tobacco and Nicotine Products
The U.S. Food and Drug Administration (FDA) has announced a multi-year, comprehensive plan for tobacco and nicotine regulation that aims to reduce tobacco-related disease...
FDA Approves Ibrutinib as First Therapy for Chronic-Graft-Versus Host Disease
The U.S. Food and Drug Administration (FDA) approved ibrutinib – a Bruton tyrosine kinase inhibitor that treats mantle cell lymphoma, chronic lymphocytic leukemia, and...
Senate Voted to Continue FDA User Fees and Passed “Right to Try” Bill
The U.S. Senate voted 94-1 to approve two pieces of health-care legislation: one that continues the U.S. Food and Drug Administration’s (FDA) authority to...
Number of Older Patients Receiving AlloHCT Increased Over the Past Decade
Historically, older adults have not been considered optimal candidates for hematopoietic cell transplantation (HCT) because of concerns about transplant-related toxicity and mortality. Over the...
Examining Nilotinib to Prevent Post-Transplant Relapse in Patients With Ph+ Leukemia
In previous research published in Blood, Paul A. Carpenter, MBBS, from the Fred Hutchinson Cancer Research Center in Seattle, Washington, and co-authors determined that...
Current Issue
August 2017, Volume 3, Issue 10
This issue features a comparison between American and European drug approval processes, a conversation with a lymphoma doctor running for Congress, highlights from recent hematology/oncology meetings, and more.
